30-day and 1-year mortality after a first myocardial infarction (MI) are both increased (OR 1.44 [95% CI 1.25–1.66] and 1.82 [95% CI 1.51–1.94], respectively) in patients with autoimmune rheumatic diseases (AIRDs) versus other patients with MI, according to the results of a new population-based study conducted in Australia. Moreover, patients with AIRDs are substantially less likely than non-AIRD patients to undergo percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery within 90 days of their first MI. This difference in intervention rates might reflect the increased rates of comorbidities (such as lung, liver and kidney disease, which are also risk factors for post-MI mortality and morbidity) in the AIRD cohort. The researchers call for further studies to investigate whether inflammatory markers might help to identify patients with AIRDs at high cardiovascular risk, and to evaluate the effect of anti-inflammatory therapies on cardiovascular risk in this group.
References
Van Doornum, S. et al. Increased 30-day and one-year mortality rates and lower coronary revascularization rates following acute myocardial infarction in patients with autoimmune rheumatic disease. Arthritis Res. Ther. 10.1186/s13075-015-0552-2
Rights and permissions
About this article
Cite this article
Poor MI outcomes linked to autoimmune rheumatic disease. Nat Rev Rheumatol 11, 196 (2015). https://doi.org/10.1038/nrrheum.2015.37
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.37